OncoMatch/Clinical Trials/Mesothelioma
Mesothelioma Clinical Trials
OncoMatch filters Mesothelioma trials by the molecular markers that determine eligibility — BAP1, NF2, CDKN2A, TP53, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaTop recruiting Mesothelioma trials
Ranked by phase and number of US sites. See all trials matched to your profile →
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
AstraZeneca
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
How OncoMatch finds Mesothelioma trials for you
AI reads the protocol
Every Mesothelioma trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Mesothelioma and mark your biomarker results — BAP1, NF2, CDKN2A — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.